Amyloid-beta Targeted Therapeutic Approaches for Alzheimer's Disease: Long Road Ahead

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment and cognitive decline. The obvious pathological features of AD are still amyloid plaques and neurofibrillary tangles. Development of disease-modifying treatments for AD has been challenging, with almost all drugs aborted. The amyloid cascade concept has been questioned due to the failures of various amyloid-targeting prospects. Despite this, targeting amyloid-beta (A beta) active immunotherapy provided some positive results to support this hypothesis and clinical trials of these candidates are ongoing. In this review, we describe the latest advance in therapeutic strategies based on amyloidogenic processing and evaluate the pros and cons of each treatment strategy. We also highlight the current status of the hottest immunotherapy and discuss the future development direction.

Automated summary

Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory impairment and cognitive decline. Despite the challenges in developing disease-modifying treatments targeting amyloid plaques, recent studies have shown that active immunotherapy against amyloid-beta may have positive effects.